This discrepancy may arise from the fact that CDC25B overexpression can promote the AF2 domain of the AR to recruit CDC25B, thereby enhancing AR activation in prostate adenocarcinoma. The gene discussed is CDC25B; the disease is prostate adenocarcinoma.